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96 Incidence of nephrotoxicity associated with concomitant
colistimethate and vancomycin use in cystic ﬁbrosis patients
M. Adeola1, A. Coralic1, S. Hart1, T.L. Barto2, M. Katz2,3. 1The Methodist Hospital,
Pharmacy, Houston, United States; 2Baylor College of Medicine, Division of
Pulmonary, Critical Care, and Sleep Medicine, Houston, United States; 3Texas
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Objectives: Acute renal failure is not a characteristic presentation in cystic ﬁbrosis
(CF). However, pulmonary exacerbation may require treatment with potentially nephro-
toxic antibiotics. Nephrotoxicity occurs in 3−5% of CF patients on colistimethate [1],
but the risk with concomitant vancomycin use is unknown. We compared the incidence
of acute kidney injury (AKI) with colistimethate alone (C) or in combination with
vancomycin (C+V).
Method: Retrospective review of CF patients admitted from August 2008 − August
2012 on intravenous colistimethate. Exclusion criteria: antibiotic therapy <72 hours,
baseline ESRD and pregnancy. Outcomes evaluated: AKI deﬁned by the RIFLE
criteria [2], change in serum creatinine and length of stay (LOS).
Conclusion: Preliminary ﬁndings reveal that the incidence of AKI was signiﬁcantly
increased with C+V compared to C alone (15.4% vs. 0%, p = 0.047). Median LOS was
also greater with C+V (12 vs. 8 days, p = 0.019). In both groups, median colistimethate
daily dose was similar (4.6 vs. 4.7mg/kg, p = 0.86). Increased LOS with C+V may be
secondary to AKI management, or conversely may represent a cohort of patients with
more severe disease.
C (N= 28) C+V (N= 26) P value
Demographics
Median age (IQR) 26 (22, 29) 25 (23.8, 27) 0.473
Median FEV1 % (IQR) 52 (33, 68) 45 (27.3, 53.8) 0.091
Outcomes
AKI (%) 0 (0) 4 (15.4) 0.047
Median LOS (IQR) 8 (6.3, 11) 12 (7, 16.5) 0.019
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Microorganisms from extreme environments, such as Antarctica, are interesting
since they have adopted peculiar survival strategies e.g. the synthesis of unusual
bioactive molecules inhibiting the growth of other bacteria. In this work 26 Antarctic
bacterial strains afﬁliated to different genera were tested for their ability to produce
new natural drugs active versus member of the Burkholderia cepacia complex
(Bcc), relevant pathogens in Cystic Fibrosis (CF) patients. The experiments were
performed adopting the cross-streaking method using as target a panel of 40 Bcc
strains. Moreover we tested the inﬂuence of the growth media on the ability of
these Antarctic bacteria to inhibit the growth of Bcc species. To this purpose cross-
streak experiments were carried out using Petri dishes with a central septum. The
tester strains were grown on three different media, MA, TYP and PCA whereas
Bcc (target) strains were grown only on PCA medium. Data obtained clearly
revealed that most of Antarctic bacteria completely inhibit the growth of all the Bcc
strains, probably through the production of a combination of diffusible and volatile
molecules. Furthermore the production of such molecules may vary depending
on the medium the tester strains are grown in. Further experiments performed
by the SPME-GC-MS technique, revealed the production of different compounds.
Finally these data highlight the potentiality of Antarctic bacteria as novel sources of
antibacterial substances. For this reason the genomes of these 26 Antarctic strains
were sequenced and assembled and further analysis will be conducted in order to
identify the gene sets involved in the production of the volatile compounds.
98 Searching for new antimicrobial targets in Burkholderia genus:
In silico analysis of the RND superfamily
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The genus Burkholderia includes a variety of species, with opportunistic human
pathogenic strains, whose increasing resistance to antibiotics has become a public
health problem. A major role in multi-drug resistance could be played by multidrug
efﬂux pumps belonging to the RND superfamily, an ubiquitous group of proteins
that appears to be mainly involved in antibiotic resistance in Gram− bacteria.
Objectives and Methods: We performed a deep analysis of the distribution of
representatives of all the 8 families belonging to this superfamily in 26 Burkholderia
completely sequenced genomes, to evaluate their possible use as a target for novel
antimicrobial drugs. A total of 417 putative RND proteins were identiﬁed. Through
different in silico analyses, most of these sequences were characterized and a core
of proteins conserved in all Burkholderia genomes was identiﬁed.
Conclusion: The whole body of data obtained on the presence and distribution
of RND proteins in Burkholderia genus shed some light on both the physiological
role(s) played by these proteins and their evolution in this genus; besides, the core of
proteins identiﬁed might serve as a basis for experimental tests, already in progress,
aimed at checking their possible use as novel targets in antimicrobial therapy against
Burkholderia species.
Lastly, the analyses performed allowed to reﬁne the genome annotation of the
genomes analyzed.
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identiﬁcation of bacteria commonly isolated from cystic ﬁbrosis
patients
A. Abdul Wahab1, S.J. Taj-Aldeen1, M. Abu-Madi2, E. Talaq2. 1Hamad Medical
Corporation, Doha, Qatar; 2University of Qatar, Doha, Qatar
Introduction: The accurate identiﬁcation of pathogenic organisms from the respira-
tory secretions of cystic ﬁbrosis (CF) patients is important to infection management
and epidemiology. Routine phenotypic methods may lead to misidentiﬁcation
of bacteria. The development of MALDI-TOF-MS devices has revolutionized
the routine identiﬁcation by introducing an easy, rapid, and low-cost technique.
The objective was to identify common bacterial isolates from CF patients by
MALDI-TOF-MS.
Methods: Fifty three patients were enrolled and 85 specimens cultured for isolation
of bacteria. We tested 125 isolates by routine phenotypic test including Vitek II,
and by MALDI-TOF (Bruker).
Results: A total 13 bacterial species were evaluated using MALDI-MS identiﬁed
isolates to species level (98% score >2) of tested isolates with genus agree-
ment in 100%. Isolates were Staphylococcus aureus (n = 50, 40%), Pseudomonas
aeruginosa (n = 40, 32%), Haemophilus inﬂuenzae (n = 17, 13.6%), Achromobac-
ter xylosoxidans (n = 6, 4.8%), Streptococus pyogens (n = 2, 1.6%), Haemophilus
parahaemolyticus (n = 2, 1.6%), Streptococus pneumonae (n = 2, 1.6%), and (n = 1,
<1%) for each Moraxella catarrhalis, Chrysobacterium gleum, Enterococcus
cloacae, Haemophilus parainﬂuenzae, Neisseria perﬂava, and Stenotrophomonas
multophilia.
Discrepant isolates were two isolates of Achromobacter sp. identiﬁed by MALDI-
MS as Achromobacter xylosoxidans (score >2), and Neiseria sp. identiﬁed as
Neisseria perﬂava (score >2).
Conclusion: We demonstrated complete genus, species agreement with MALDI-
MS compared to routine phenotypic identiﬁcation. MALDI-MS will decrease time
to results to optimize early antimicrobial therapy in CF patients.
